Ivabradine and AF: Coincidence, Correlation or a New Treatment?
| Autor: | Haitham Badran, Yehia Saleh, Mahmoud Abdelnabi, Ashraf E. Ahmed, Abdallah Almaghraby |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Electrophysiology and Ablation Cardiomyopathy If channels heart failure angina Angina Physiology (medical) Internal medicine Heart rate heart rate Medicine Diseases of the circulatory (Cardiovascular) system Ivabradine acute coronary syndromes Sinus rhythm Myocardial infarction If current business.industry Atrial fibrillation AF medicine.disease Heart failure RC666-701 Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Arrhythmia & Electrophysiology Review, Vol 8, Iss 4, Pp 300-303 (2020) Arrhythmia & Electrophysiology Review |
| ISSN: | 2050-3369 2050-3377 |
| Popis: | Ivabradine is a heart rate-lowering agent that inhibits pacemaker funny current (If). It has been approved by the European Medicines Agency and the US Food and Drug Administration for patients with stable angina and heart failure (HF). AF is a common issue especially in ischaemic heart disease and HF patients. In contrast to experimental findings and a limited number of clinical trials that demonstrate the emerging role of ivabradine for heart rate control in AF or maintenance of sinus rhythm, there is accumulating contradictory data indicating that there is, in fact, an increased incidence of new-onset AF among people who are taking ivabradine in clinical practice. This article reviews the most recent evidence highlighting the diversity of data in relation to the use of ivabradine and the onset of AF and whether it has a legitimate role in AF treatment and the maintenance of sinus rhythm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|